We collaborate with more than 100 VAD centers.
A specialized HF team is assigned to each case, including an intake specialist, HF nurse, pharmacist, dietitian, clinical liaison, and reimbursement specialist. Our clinical liaisons are embedded within health institutions and collaborate with more than 100 transplant/VAD centers to customize treatment plans that meet the protocols of each physician and/or transplant center providing care for a patient. Our care is also designed in accordance with the ACCF/AHA Guidelines.
ACCF=American College of Cardiology Foundation; AHA=American Heart Association; VAD=ventricular assist device.
Time-saving intake coordination
Option Care begins coordinating care and financial assistance before the patient is discharged from the hospital. Our team of specialists manage insurance verification and prior authorization processes for patients and healthcare professionals. More than 99% of our referrals are approved, including CMS authorization approvals.1 We communicate cost of care and coverage details to patients. Our clinicians give patients and caregivers one-on-one counseling prior to discharge and assist with each patient’s transition to an ambulatory pump during discharge.
CMS=Centers for Medicare & Medicaid Services.
Individualized care plans
86% of patients in our stage D heart failure program meet their therapy goals.1 What makes Option Care’s inotropic home infusion therapy services so effective is a customized care plan. By aligning ACCF/AHA Guidelines for continuous inotropic infusion with each patient’s therapy goals, we provide customized protocols that are adaptable to patient needs in accordance with transplant/VAD center or palliative care protocols. Option Care offers a robust solution for HF patients. Beyond inotropic therapy, we also provide high-quality supportive care, including nutritional support and anti-infectives administration.
Clinical monitoring and reporting
Option Care monitors and tracks HF patient outcomes and compliance with weekly home visits and pharmacy follow-up calls. Our regular patient monitoring helps minimize exacerbations and reduce hospital readmissions. Option Care notifies physicians and healthcare providers of adverse changes in patient status and provides routine updates at intervals designated by their referring provider.
Long-term support and education
Before hospital discharge, Option Care provides patients and caregivers with one-on-one education about inotropic home infusion and self-care information. After discharge, our clinicians provide ongoing education throughout treatment. Patients are provided a complete self-monitoring kit, which includes an HF education booklet, quick reference guide to exacerbations, a logbook to record vital information, and self-monitoring tools. Option Care also provides 24/7 patient support with experienced clinicians.
Hear about the experience of heart failure patient Mike G. and his wife Mary Kay
Option Care home inotropic infusion therapy helps break the “cycle of exacerbation”—or the cycle of ED visits and hospital readmissions. Exacerbation of HF symptoms is a repetitive and costly sequence that burdens patients and healthcare systems. 84% of our patients receiving inotropic therapy had ≤1 hospital readmission while on service. In fact, our patients had a 30-day hospital readmission rate–even lower than the national average of those with less advanced heart failure.2,3*
The reductions in hospital readmissions result in significant cost savings. Over a 5-year period, Option Care demonstrated a 0.295 per-patient reduction in annual hospital readmissions, which translates to $17,187 in annual cost savings per patient.4,5†
*Option Care rate is based on 2008 data, which include only stage D heart failure patients in our inotropic therapy program. National readmission rate was calculated from Medicare data for patients with various stages of heart failure who were discharged July 2007 through June 2010. †Based on an average stage D heart failure hospitalization cost of $58,260 per patient-year.
Palliative care, together with inotropic therapy, allows more end-of-life patients to manage their symptoms and spend their final days at home.6‡
‡Palliative care aims to ease the course of advanced illnesses and to improve the quality of life for patients and their families. Unlike hospice care, which is available only during a patient’s final months of life, palliative care is available at any time during the course of a serious or life-threatening illness.
References: 1. Data on file, Option Care. 2. Retrospective chart review of Option Care data collected January 1, 2004-December 2008. 3. Joint Commission Quality Report Hospital. http://www.qualitycheck.org/QualityReport.aspx?hcoid=5503. Access February 26, 2015. 4. Taitel M, Meaux N. Hospital admission reductions among stage D heart failure patients participating in a home inotropic infusion program (abstract). Heart Lung. 2011;40(4):366. 5. Meaux N, Taitel MS. Hospital admission reductions among stage D heart failure patients participating in a home inotropic infusion program. Poster presentated at: 7th Annual Meeting of the American Association of Heart Failure Nurses; June 23-25, 2011; Seattle, WA. 6. Taitel M, Meaux N, Pegus C, Valerian C, Kirkham H. Place of death among patients with terminal heart failure in a continuous inotropic infusion program. Am J Hosp Palliat Care. 2012;29(4):249-253.
Sign up to receive more information and periodic updates about Option Care.